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Abstract 
Breast cancer (BC) is the most common cancer and the second cause of mortality in women all around the world. 
It is caused by several factors including genetic determinants, so that both genetic susceptibility factors and 
environmental factors are involved in the etiology. Significance of genes functioning in steroid hormone synthesis 
and metabolism are well established in breast cancer susceptibility. Polymorphisms of genes encoding enzymes 
involved in estrogen biosynthesis pathway and in the metabolic activation of pro-carcinogens to genotoxic 
intermediates, such as cytochrome P450C17α (CYP17) was closely examined in this women-based case control 
study of Iraqi women aged range (27–91). The associations between selected single nucleotide polymorphisms 
(SNPs) in the CYP17 gene and breast cancer for 105 women with breast cancer and 120disease- free controls were 
evaluated. Restriction fragment length polymorphism (RFLP) technique was used with MspA1 digested enzyme 
for the PCR products. There was no significant C→T (rs743572) CYP17 associated with breast cancer in the Iraqi 
women studied. 
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Introduction 
Breast cancer (BC), is a disorder of cell growth. BC is a dynamic population of abnormal somatic cells evolving 
through natural selection [1] (Fortunato at el. 2017). It is the most frequent malignant neoplasm among female 
worldwide, accounts for approximate 25% of women malignant tumor. It is reported that 1.67 million people were 
diagnosed for BC every year; therefore it has become a serious health issue, especially in the developing countries 
[2] (Theodoratou et al.; 2018). The risk of breast cancer is related to genetic, environmental, and lifestyle factors 
that influence the level of exposure to estrogens and other sex hormones [3-5] (Feigelson et al., 1996, Lichtenstein 
et al., 2000, Bhatia, 2015). It is well established that the lifetime presence of the estrogen in the blood is one of the 
important risk factors for breast cancer, and this is in consistence with the low incidence of the breast cancer in 
males due to their lower estrogen levels and lower breast tissue volume [6] (Germain, 2011). Furthermore, there 
is a plethora of evidence suggesting the positive role of cell surface receptors of estrogen and progesterone in 
tumorigenesis [7,8]. Several genes have been found to be involved in synthesis, function, metabolism and secretion 
of the steroid hormones. The most important of them is the P450 family. Among genes of this family, CYP17, 
CYP19 and CYP1A1 have important functions in synthesis, metabolism and maintaining the levels of the androgen 
and estrogen hormones, located on10q24.3, 15q21.2 and 15.q24.1 respectively [13] (Bugano et al., 2008). Much 
interest has long been focused on cytochrome P450c17α (CYP17) and glutathione S-transferase 1 (GSTP1) genes, 
encoding enzymes involved in estrogen biosynthesis and metabolism [14] which encodes steroid (17-alpha-
hydroxylase) also known as a steroid 17-alpha-monooxygenase. It performs both 17-alpha-hydroxylase and 17, 
20-lyase activity. Functions of this enzyme allow the adrenal glands and gonads to synthesize both 17-alpha-
hydroxylated glucocorticoids (via 17-alpha-hydroxylase activity) and sex steroids (via 17, 20-lyase activity)[9-12] 
or in environmental carcinogens detoxification and exo- and endogenous xenobiotic transformation [15], 
respectively. Several polymorphisms in many different genes have been claimed to be associated with the risk of 
BC. Some studies have confirmed a link between CYP17 [16-20] gene polymorphisms and the risk of BC, Hence, 
the clinical relevance of these polymorphic genes remains to be fully elucidated and needs further investigation 
[21]. In view of strong evidence implicating the importance of CYP17A1 in androgen metabolic pathways, the 
present study aimed at genotyping − 34T>C (rs743572) of CYP17A1. As of yet, no study has been conducted to 
see association of this SNP with breast cancer in Iraq. This study will help in generating baseline data. 
  
Material and Methods 
1. Patients 
The study protocol followed the guidelines of our local ethics committee and the investigation was conducted with 
the ethical requirements defined in the Iraq. All patients gave their informed consent to participate in the study. 
The current study include 105 samples (30 fresh tissue+ 75 blood) of Iraqi women with breast cancer ER+ and 
120 (30 fresh tissue+ 90 blood samples) healthy women as a control. Iraqi women with a clinical and histological 
diagnosis of breast cancer (BC) were enrolled in this study between June to July 2019 from the Middle Euphrates 
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cancer center, Najaf and medical city/Baghdad, Iraq. 
 
2. DNA Extraction and genotyping 
Genomic DNA was extracted from whole fresh blood, using gSYNC DNA Extraction Kit (Geneaid, Taiwan) and 
Thermo Scientific GeneJET Genomic DNA Purification Kit (ThermoFisher, USA) for fresh tissue samples after 
preserved the samples in RNAlater® Tissue Collection: RNA Stabilization Solution (ThermoFisher, USA)  in -
80C. The nucleotide sequence of primers is using primers (sense, 5'- CATTCGCACTCTGGAGTC-3, antisense, 
5-AGGCTCTTGGGGTACTTG-3). PCR amplification of rs743572 (− 34T>C) was carried after optimization of 
temperature annealing for different degree (51,53,55,57,59) to choose the perfect temperature annealing for this 
specific primer, with this conditions:  95C for 5min, 95 30 sec, 55C for 1 min ,72 for  30 sec and 72C for 10 min. 
After amplification, the PCR products were digested with the restriction endonuclease MspAI for 3 hours then 
subjected to electrophoresis through a 3% agarose gel, and visualized by staining the gel with SAFE Stain. 
Different genotypes could then be distinguished based on the size of the digested fragments. A single 414-bp 
product defined the T homozygotes; 414-, 290-, and 124-bp products defined the TC heterozygotes; and 290-bp 
and 124-bp products defined the C homozygotes. 
 
Results 
The current study included 105 breast cancer patients. Among them 93.33% were married, 23.8% were with family 
history either in the 1st or 2nd degree, 93.33% with ductal carcinoma, 73.33% in grade II and 52.38% with left 
lateral breast carcinoma. The medium patients age was 50 years with rang between 27-91years. 
Table (1): Main tumor Clinicopathological data in the patients with breast cancer 
Clinic pathological Features No (%) P-value 
Age (years) 
Mean 
Minimum 
Maximum 
 
50 
27 
91 
 
--- 
Family history 
Yes 
No  
 
25(23.8%) 
80(76.2%) 
 
0.0001 ** 
Marital Status 
Married 
Non- Married 
 
98 (93.33%) 
7 (6.67%) 
 
0.0001 ** 
Breast Type 
Ductal 
Lobular 
 
98 (93.33%) 
 7 (6.67%) 
 
0.0001 ** 
Grade 
II 
III 
 
77 (73.33%) 
28 (26.67%) 
 
0.0001 ** 
Location 
Lateral, right 
Lateral, left 
 
50 (47.61%) 
55 (52.38%) 
 
0.0981 NS 
** (P≤0.01), NS: Non-Significant. 
The purified genome DNA of the 105 tumor case and 120 control DNA samples submerge to the PCR process 
to be ready to the next step of restriction fragment length polymorphism (RFLP) with MspA1 digested enzyme 
( Figures 1, 2). Then the PCR products were analyzed by 2% agarose gel electrophoresis. The pair of primers 
amplified was expected to produce a size of 414 bp. 
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Figure (1): CYP17 annealing optimization separated at 414 bp on 2% agarose gel electrophoresis 
M: 100 BP ladder, C: control and different temperature degrees 
 
 
Figure (2): CYP17 products separated at 414 bp on 2% agarose gel electrophoresis 
M: 100 bp ladder and (1-8) CYP17 gene product 
 
 
Genotyping analysis 
The allele of gene CYP17 that has C instead of T at -34 bp was designated by the researchers who discovered this 
base pair substitution as: (A2) allele and the un-mutated allele with T at -34 bp were designated as a (A1) allele of 
CYP17(Carey, et al.; 1994 and Diamanti-Kandarakis, et al.; 1999). 
A: Genotyping analysis in the fresh tissue samples 
The variation of genotype of (rs743572) CYP17 MspA1 in the fresh tissue samples (figures (3) as a following 
(Table 2): TT (15/30) 50%, TC (7/30) 23.33% and CC (8/30) 26.66% while in the control tissue samples were: TT 
(9/30) 30%, TC (15/30) 50% and CC (6/30) 20%. 
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Figure (3): CYP17 MspA1 digested products for fresh tissue samples separated on 3% agarose gel 
electrophoresis 
Lane1(M) 100bp ladder; Lane 3 & 6 Homozygous A1 genotype (A1/A1); Lane 2, 4, 7 & 8 Heterozygous 
genotype (A1/A2); Lane 5 Homozygous A2 genotype (A2/A2). 
 
  
Table (2): Tumor Tissue sample recurrence for CYP17 alleles in Iraqi women with breast cancer and control 
Genotype Cases 
No.  (%) 
Control 
No.  (%) 
P-value O.R. (C.I.) 
(A1A1) TT 15 (50.00%) 9 (30.00%) 0.0073 ** 1.204 (0.76-1.52) 
(A1A2) TC 7 (23.33%) 15 (50.00%) 0.0066 ** 1.255 (0.81-1.56) 
(A2A2) CC 8 (26.67%) 6 (20.00%) 0.193 NS 0.778 (0.54-107) 
Total  30 (100%) 30 (100%) -- -- 
Allele  Frequency  
(A1) T 0.62 0.55 -- -- 
(A2) C 0.38 0.45 -- -- 
** (P≤0.01), NS: Non-Significant.. 
 
B: Genotyping analysis in the Blood samples 
The variation of genotype of (rs743572) CYP17 MspA1 in the blood samples (Figure 4) were as a following (Table 
3): the patients frequency were TT (34/75) 45.33, TC (28/75) 37.33% and CC (13/75) 17.33% while the control 
frequency were TT (37/90) 41.11%, TC (37/90) 41.11% and CC (16/90) 17.77%. 
Table (3): Tumor blood samples recurrence for CYP17 alleles in Iraqi women with breast cancer and control. 
Genotype Cases 
No.  (%) 
Control 
No.  (%) 
P-value O.R. (C.I.) 
TT 34 (4335%) 37 (41.11%) 0.469 NS 0.307 (0.28-0.51) 
TC 28 (37.33%) 37 (41.11%) 0.475 NS 0.281 (0.25-0.48) 
CC 13 (17.33%) 16 (17.78%) 0.892 NS 0.166 (0.09-0.33) 
Total  75 (100%) 90 (100%) -- -- 
Allele  Frequency  
T 0.64 0.62 -- -- 
C 0.36 0.38 -- -- 
NS: Non-Significant. 
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Figure (4): CYP17 MspA1 digested products for blood samples separated on 3% agarose gel electrophoresis 
Lane (M) 100bp ladder; Lane 9, 10, 14 & 15 Homozygous T genotype (TT); Lane 1, 2, 3, 4, 6, 7, 8, 11& 13 
Heterozygous genotype (TC); Lane 5 and 12 Homozygous A2 genotype (CC). 
 
The total variation of genotype of (rs743572) CYP17 MspA1 for both fresh tissue and blood samples (105 
cases+ 120 control) as a following (Table 4): the frequency of TT (414 bp) allele in the patients was 49 (46.66%), 
TC (414, 290 and 124 bp) 35 (33.33%) and CC (290 and 124 bp) 21 (20%) while in the control was: TT 46 
(38.33%), TC 52 (43.33%) and CC 22 (18.33%). 
Table (4): Total tumor samples recurrence for CYP17 alleles in Iraqi women with breast cancer and control  
Genotype Cases 
No.  (%) 
Control 
No.  (%) 
P-value O.R. (C.I.) 
TT 49 (46.67%) 46 (38.33%) 0.0966 NS 0.179 (0.094-0.29) 
TC 35 (33.33%) 52 (43.33%) 0.0472 * 0.772 (0.58-1.02) 
CC 21 (20.00%) 22 (18.33%) 0.664 NS 0.471 (0.32-0.61) 
Total  105 (100%) 120 (100%)  -- -- 
Allele  Frequency  
T 0.63 0.60 -- -- 
C 0.37 0.40 -- -- 
* (P≤0.05), NS: Non-Significant 
 
Discussion 
The statistical analysis of (Table1) data showed a significant P≤0.01 between studied clincopathological features 
except in location of breast cancer which revealed that no statistical significance between cancer if was left or right 
breast.   
The difference in the frequency of the homozygous A1A1 and A1A2 genotype between the 30 fresh tissue 
affected women with breast cancer with the 30 controls was statistically significant by P-value 0.0073 and 0.0066  
with O.R. (C.I.) 1.204 and 1.255 respectively(P≤0.01), while no significant with the A2A2 allele frequency. 
In the blood samples, there is no significant in the frequency of the homozygous A1A1, A2A2 and A1A2 
genotype allele between the 75 affected women with breast cancer and 90 controls. The final screening of the 
samples investigated the frequency of T→C substitution at -34bp from the initiation site of translation of gene 
CYP17 polymorphic (A2 allele of gene CYP17) in Iraqi women patients presenting with breast cancer ER+ and 
in matched controls, there was statistically significant by P-value 0.0472 with O.R. (C.I.) 0.772 (P≤0.05) for 
Heterozygous genotyping (A1A2) TC in control samples. There was no significant association with tumor cases. 
A study in Iraq that deals with CYP17 frequency with endometriosis disease, they observed significant 
associations between CYP17 SNPs (rs743572) and genotypes of Iraqi women with endometriosis disease [21] (Al-
Rubae, et al., 2017). While another Iraqi study done by [22] Mohammed et al., (2015) suggested that the (T/C) 
polymorphism in the CYP 17 gene was not associated with PCOS (Poly cystic ovary) in Iraqi women. 
The results of this study corroborates of a neighboring Iranian study presented by [23] (Ebrahimi et al., 2017) 
which examined genotype variation in the whole population. They found that: 72 (35.1%) were A1/A1, 104 (50.7%) 
were A1/A2 and 29 (14.1%) were A2/A2. The frequency of A1 and A2 alleles in the total population was 60.48% 
and 39.51%, respectively. 
On the other hand, there are many studies in Europe that showed no significant differences detected in either 
the allele frequencies or the genotype distributions between the control and breast cancer patients in the British 
population [24] (Dunning et al., 1998), German population [25] (Verla-Tebit et al., 2005) and in Italian [20] 
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(Antognelli et al., 2009). Furthermore, a recent Egyptian population study [26] (Youssef, et al., 2018) found that 
the A2 allele did not significantly affect the breast cancer risk. Additionally, meta-analysis studies found the 
association of CYP17 T-34C polymorphism with breast cancer susceptibility in the Chinese population including 
27,104 cases and 34,218 controls. These studies found no significant correlation between this polymorphism and 
breast cancer susceptibility [27] (Sun et al. 2018) in addition to [28] Weng et al., (2019) study. 
On the other hand, there were few studies which found correlation between CYP17 polymorphism and breast 
cancer susceptibility like India study [29] (Surekha et al., 2010) which found that: the TT genotype frequency was 
increased in breast cancer patients (68.7%) when compared to controls (55.4%). While 2018 Chinese study 
published by [30] Yang and his colleagues suggested that CYP17 polymorphisms may reduce the susceptibility to 
breast cancer in Chinese women. 
 
Conclusion  
The findings in the current study revealed that there is no significant correlation between CYP17 polymorphism 
and breast cancer susceptibility with allele frequency 0.63 for T and 0.37 for C. The results of many studies that 
examined the association between MspA1 CYP17 variant and breast cancer were inconsistent. The wide variation 
in these studies may come from the difference in study methods and perhaps some of these studies were not 
population based which may be affected by selection bias. Also studies differ markedly in size number of patients 
and control so they varied in statistical significance. 
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